Results 191 to 200 of about 401,649 (316)

HLA allele DRB1*01:03: the genetic link to neutralizing IL-10 antibodies in inflammatory bowel disease. [PDF]

Signal Transduct Target Ther
Mattner J.
europepmc   +1 more source

Assessment of Gibbs Free Energy Calculation in PI‐Controlled Heating

Chemie Ingenieur Technik, EarlyView.
For description and control of chemical processes in lab or industry thermodynamic variable Gibbs free energy provides opportunity to compare and interpret phenomena, even on a quantitative level. In a case study for PI‐controlled heating, impacts on its limits from control delay until parameter quantization are highlighted and assessed.
Jannik Dutschke, Samira Johanna Geiger, Liane Andrea Haufe, Sebastian Kaiser, Markus Seifert   +4 more
wiley   +1 more source

Characterization of NAT2 Using Long‐Read Sequencing: Allele, Diplotype, and Phenotype Call Accuracy Compared to Other Testing Strategies

Clinical Pharmacology &Therapeutics, EarlyView.
The NAT2 pharmacogene is essential in drug metabolism, particularly for aromatic amines and hydrazines. Genetic variations in NAT2 categorize individuals as rapid, intermediate, or poor metabolizers based on their acetylation capacity to inform dosing guidelines.
Shobana John, Erin C. Boone, Byunggil Yoo, Laura B. Ramsey, Andrea Gaedigk   +4 more
wiley   +1 more source

The Role of Human Leukocyte Antigen (HLA) Allele Patterns in the Incidence of End-Stage Renal Disease and HLA Antibody Production: Protocol for a Case-Control Study. [PDF]

JMIR Res Protoc
Puspitawati I, Kertia N, Triyono T.
europepmc   +1 more source

Clinical Significance of Acute Kidney Injury in Idiosyncratic Drug‐Induced Liver Injury: A Multicentric Propensity Scores Matched Study

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical significance of acute kidney injury in idiosyncratic drug‐induced liver injury: a multicentric propensity scores matched study. Evidence about the role of acute kidney injury (AKI) in idiosyncratic drug‐induced liver injury (DILI) is still scarce.
José María Pinazo‐Bandera, Hao Niu, Juan Pedro Toro‐Ortiz, Inmaculada Medina‐Caliz, Judith Sanabria‐Cabrera, Aída Ortega‐Alonso, Mercedes Robles‐Díaz, Daniel Enrique Di Zeo‐Sanchez, Nelia Hernández, Fernando Bessone, Vinicius Nunes, Raymundo Paraná, M. Isabel Lucena, Raul J. Andrade, Ismael Alvarez‐Alvarez, Miren García‐Cortés   +15 more
wiley   +1 more source

High-resolution characterization of classical and non-classical HLA diversity reveals important admixture in Brazilian indigenous. [PDF]

Front Genet
De Freitas Centurião N, Francisco LC, Lafer MM, Sitnik R, Rebello Pinho JR, Groetares GL, Alonso EO, Maciel GC, Torres MA.   +8 more
europepmc   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source

Antigen specificity and inflammatory amplification in autoimmune hepatitis. [PDF]

Front Immunol
Xu Z, Liu Y, Zou H, Guo S.
europepmc   +1 more source

Implementation of Pharmacogenomics in Pediatric‐Focused Institutions Within the Pharmacogenomics Global Research Network

Clinical Pharmacology &Therapeutics, EarlyView.
Descriptions of how pediatric‐focused institutions implement pharmacogenomic testing are scarce, and often not differentiated from adult‐focused institutions. We aimed to provide a detailed description of how pediatric‐focused institutions across the world implemented pharmacogenomic testing in clinical practice.
Laura B. Ramsey, Chad Bousman, Rebecca Brand, Kelsey Cook, David B. Gregornik, Cyrine E. Haidar, Nancy Hakooz, Nicole Keuler, Nathan Lamb, Mohamed Nagy, Jenny Q. Nguyen, Courtney Paetznick, April Schultz, D. Max Smith, Evangelia Eirini Tsermpini, Amanda L. Elchynski   +15 more
wiley   +1 more source